Supplementary Data — Phthalocyanine reduces COVID-19 risk: real-time meta analysis of 4 studies

@CovidAnalysis, November 2025, Version 3V3
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Poleti (DB RCT) 29% 0.71 [0.53-0.96] no recov. 29/59 52/75 Improvement, RR [CI] Treatment Control Poleti (DB RCT) 22% 0.78 [0.63-0.97] no recov. 38/59 62/75 Poleti (DB RCT) 46% 0.54 [0.30-0.98] no recov. 12/59 28/75 Poleti (DB RCT) 32% 0.68 [0.42-1.09] no recov. 17/59 32/75 da Silva.. (DB RCT) 85% 0.15 [0.01-2.66] death 0/20 3/21 da Silva.. (DB RCT) 92% 0.08 [0.01-0.68] ICU 0/20 6/21 da Silva.. (DB RCT) 54% 0.46 [0.23-0.93] hosp. 20 (n) 21 (n) Colado .. (DB RCT) 51% 0.49 [0.29-0.83] viral load 15 (n) 15 (n) Colado .. (DB RCT) 38% 0.62 [0.36-1.06] viral load 16 (n) 15 (n) Colado .. (DB RCT) 72% 0.28 [0.08-1.04] viral load 15 (n) 15 (n) Colado .. (DB RCT) 68% 0.32 [0.09-1.17] viral load 16 (n) 15 (n) Brito-Reia 54% 0.46 [0.20-1.08] cases 6/1,153 44/3,887 Phthalocyanine COVID-19 outcomes c19early.org November 2025 Favors phthalocyanine Favors control
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.